At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,055 enrolled
Drug / intervention
Mammalian cell based flu vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Observer Blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety of a Trivalent Subunit Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Chicken Eggs (Fluvirin®), in Healthy Children and Adolescents 4 to 17 Years of Age.
In Brief
A Phase 3 clinical trial evaluating Mammalian cell based flu vaccine and Egg based flu vaccine for Influenza and Fever. Completed, enrolled 2,055 participants across 34 sites in 5 countries.
Detailed Summary
Evaluate safety and tolerability of TIVa or TIVb vaccine in healthy children and adolescents 4 to 17 years of age.
Study Details
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2013
First PostedMay 2013
Primary CompletionJun 2014
TodayJul 2026
First PostedMay 20, 2013
Enrollment StartMay 1, 2013
Primary CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 13.1 years ago
Interventions
Mammalian cell based flu vaccinebiological
Egg based flu vaccinebiological